Abstract
Praziquantel (PZQ) is an essential medicine for treating parasitic flatworm infections such as schistosomiasis, which afflicts over 250 million people. However, PZQ is not universally effective, lacking activity against the liver fluke Fasciola. The reason for this insensitivity is unclear, as the mechanism of PZQ action is unknown. Here, we show PZQ activates a transient receptor potential melastatin ion channel (TRPMPZQ) in schistosomes by engaging a hydrophobic ligand binding pocket within the voltage-sensor like domain to cause Ca2+ entry and worm paralysis. PZQ activates TRPMPZQ homologues in other PZQ-sensitive flukes, but not Fasciola. However, a single amino acid change in the Fasciola TRPMPZQ binding pocket, to mimic schistosome TRPMPZQ, confers PZQ sensitivity. After decades of clinical use, the basis of PZQ action at a druggable TRP channel is resolved.
Publisher
Cold Spring Harbor Laboratory
Reference37 articles.
1. Human schistosomiasis
2. The unacknowledged impact of chronic schistosomiasis
3. Schistosomiasis — Assessing Progress toward the 2020 and 2025 Global Goals
4. Ending the neglect to attain the Sustainable Development Goals – A road map for neglected tropical diseases 2021-2030. World Health Organ. Monogr. Ser., (2020).
5. Antiparasitics in Animal Health: Quo Vadis?;Trends Parasitol,2021